Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove

Cancer Research

Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression

Published: February 3, 2023 doi: 10.3791/65047
* These authors contributed equally


This study developed a noninvasive and real-time method to evaluate the distribution of programmed death-ligand 1 in the whole body, based on positron emission tomographic imaging of [68Ga] D-dodecapeptide antagonist. This technique has advantages over conventional immunohistochemistry and improves the efficiency of identifying appropriate patients who will benefit from immune checkpoint blockade therapy.


The development of immune checkpoint blockade therapy based on programmed cell death-protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) has revolutionized cancer therapies in recent years. However, only a fraction of patients responds to PD-1/PD-L1 inhibitors, owing to the heterogeneous expression of PD-L1 in tumor cells. This heterogeneity presents a challenge in the precise detection of tumor cells by the commonly used immunohistochemistry (IHC) approach. This situation calls for better methods to stratify patients who will benefit from immune checkpoint blockade therapy, to improve treatment efficacy. Positron emission tomography (PET) enables real-time visualization of the whole-body PD-L1 expression in a noninvasive way. Therefore, there is a need for the development of radiolabeled tracers to detect PD-L1 distribution in tumors through PET imaging.

Compared to their L-counterparts, dextrorotary (D)-peptides have properties such as proteolytic resistance and remarkably prolonged metabolic half-lives. This study designed a new method to detect PD-L1 expression based on PET imaging of 68Ga-labeled PD-L1-targeted D-peptide, a D-dodecapeptide antagonist (DPA), in tumor-bearing mice. The results showed that the [68Ga]DPA can specifically bind to PD-L1-overexpressing tumors in vivo, and showed favorable stability as well as excellent imaging ability, suggesting that [68Ga]DPA-PET is a promising approach for the assessment of PD-L1 status in tumors.


The discovery of immune checkpoint proteins was a breakthrough in tumor therapy, and has led to major advances in the development of immune checkpoint blockade therapy1. Programmed cell death-protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) are potential drug targets with several antibodies approved by the Food and Drug Administration (FDA). PD-1 is expressed by tumor-infiltrating immune cells, such as CD4+, CD8+ T cells, and regulatory T cells. PD-L1 is one of the PD-1 ligands, which is overexpressed in a variety of tumor cells2,3. The interaction between PD-1 and PD-L1 inactivates PD-1, thus suppressing the antitumor immune response4. These findings suggest that the inhibition of PD-L1 can improve the killing effect of immune cells and eliminate tumor cells5. Currently, chromogenic immunohistochemistry (IHC) is the most commonly used approach to identify patients who are most likely to respond to immune checkpoint therapy6,7. However, due to the heterogeneous expression of PD-L1 in tumor cells, IHC results from biopsies cannot provide accurate information about PD-L1 expression in patients8. Previous studies have reported that only 20%-40% of patients gain long-term benefits from immune checkpoint blockade therapy1,9,10. There is, therefore, an urgent need to develop a new method to circumvent the false-negative results caused by the heterogeneous expression of these immune checkpoint proteins.

Molecular imaging technology, such as positron emission tomography (PET), enables real-time visualization of the whole body in a noninvasive way, and thus can outperform the conventional IHC method11,12,13. Radiolabeled antibodies, peptides, and small molecules are promising tracers for monitoring PD-L1 expression in cancer patients14,15,16,17,18,19,20,21,22,23,24,25. The FDA has approved three PD-L1 therapeutic monoclonal antibodies: avelumab, atezolizumab, and durvalumab26. Immuno-PET tracers based on these antibodies have been well documented27,28,29,30,31,32. Early-phase clinical trials have revealed limited value for clinical application, because of the unfavorable pharmacokinetics30. Compared with antibodies, peptides exhibit faster blood and organ clearance from healthy organs, and can be easily chemically modified33. Multiple peptides with high affinities for PD-1/PD-L1 have been reported2; WL12 is a reported peptide that shows specific binding to PD-L134. Radiolabeled tracers, [64Cu]WL12, [68Ga]WL12, and [18F]FPyWL12, have been reported to show high in vivo specific tumor-targeting ability, which allows for the harvest of high-quality images of PD-L1 expression in tumors26,35,36,37. Moreover, the first in-human evaluation of radiolabeled WL12 has demonstrated that [68Ga]WL12 (chelated by NOTA) has a safe and efficient potential for clinical tumor imaging38. Due to its high hydrophobicity and high uptake in the healthy liver, WL12 has limited clinical use. Other radiolabeling peptides, such as TPP1 and SETSKSF, which specifically bind to PD-L1, have also showed potential stability and specificity to visualize whole-body PD-L1 expression39,40. However, unmodified peptides are easily degraded by proteases, and are rapidly metabolized by the kidney. Dextrorotary(D)-peptides have been widely used as effective mediators, due to the poor stability of left-handed (L)-peptides41,42,43. D-peptides are hyper-resistant to proteolytic degradation and have remarkably prolonged metabolic half-lives. Compared with their L-counterparts, D-peptides mostly show specific binding abilities44,45,46.

This study designed a new method to detect PD-L1 expression, based on PET imaging of a 68Ga-labeled PD-L1-targeted D-peptide, D-dodecapeptide antagonist (DPA), in a tumor-bearing mouse model47. The stability of [68Ga]DPA was first studied in phosphate-buffered saline (PBS) and mouse serum, after which the binding affinity of [68Ga]DPA in PD-L1-overexpressing tumors was tested. Thereafter, PET imaging was performed in glioblastoma xenograft models to confirm whether [68Ga]DPA was an ideal PET tracer to monitor PD-L1 expression in tumors. The combination of PET imaging and DPA not only provides a new approach to overcome challenges associated with the heterogeneous expression of PD-L1, but also lays the basis for the development of D-peptide-based radiotracers.

Subscription Required. Please recommend JoVE to your librarian.


The animal experimental procedures were approved by the Animal Ethics Committee of Nanjing Medical University or the National Institutes of Quantum Science and Technology. Mice experiments were strictly performed in compliance with the institutional guidelines of the Committee for the Care and Use of Laboratory Animals.

1. Peptide synthesis

  1. Swell 100 mg of 4-methylbenzhydrylamine (MBHA) resin (loading capacity of 0.37 mmol/g) in 1 mL of N-methyl-2-pyrrolidone (NMP) for 30 min under mild N2 bubbling.
  2. Prepare a fresh stock buffer consisting of Fmoc-protected amino acids (5.0 equiv), HCTU (4.9 equiv), and DIPEA (10.0 equiv) in 1 mL of NMP, and add to the resin (100 mg). Allow the coupling reaction to proceed for 1.5-2 h.
  3. Prepare deprotection buffer consisting of 50% (vol/vol) morpholine in NMP. Wash the resin (100 mg) 2 x 30 min with 1 mL of the deprotection buffer in each wash to remove the Fmoc group on the amine group. Wash the resin with dichloromethane (DCM; 1 mL) for 1 min, remove the DCM, and rewash the resin with NMP (1 mL) for another 1 min. Next, remove the NMP and rewash the resin with DCM for 1 min.
    NOTE: All the washing procedures are conducted under mild N2 bubbling. The above procedures are repeated until the last amino acid.
  4. For adding 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) to the peptide, pre-activate the DOTA with N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC·HCl) and N-hydroxysuccinimide (NHS). Incubate the stock buffer of DOTA/EDC·HCl/NHS at a molar ratio of 1:1:1 in dimethyl sulfoxide (DMSO) for 3 h, with a final DOTA concentration of 1 M. Next, add the stock buffer (1 mL) to the resin (100 mg), and allow the reaction to proceed for 2 h with gentle N2 bubbling.
    NOTE: 1,4,7-triazacyclononane-1,4,7-triacetic acid (NOTA) can also be utilized as a chelator for 68Ga complexation. The same procedures can be used for NOTA coupling.
  5. Rinse the resin thoroughly from the top using DCM and apply a vacuum to remove residual reaction solution simultaneously. Rinse the resin 3x using DCM (1.5 mL), and then rinse with MeOH (1.5 mL) to shrink the resin. Put the resin under nitrogen overnight, or under high vacuum for at least 4 h, until the resin becomes dry.
  6. Place the dried DPA peptide-containing resin in a 2 mL polypropylene container with a screw cap. Add the appropriate cleavage cocktail (95/2.5/2.5 TFA/TIS/H2O in volume; 1 mL/100 mg resin) and seal the container tightly using a screw cap. Gently agitate the reaction on an orbital shaker in a fume hood at 20-25 °C for 2 h.
    CAUTION: Prepare trifluoroacetic acid (TFA) in a fume hood wearing protective clothing, due to its highly corrosive nature.
  7. Remove most of the TFA by evaporation under nitrogen in the fume hood. Precipitate the peptides by adding diethyl ether (~1.5 mL/100 mg of resin).
  8. Vortex the mixture to triturate the peptides and centrifuge at room temperature (10,000 × g, 5 min). Carefully pour the solvent out of the container. Repeat steps 1.7-1.8.
  9. Air-dry the residue in the open container for 10 min. Add 50% (vol/vol) aqueous acetonitrile, and vortex for 1-2 s to dissolve the products (1 mL/100 mg of resin).
  10. Remove the resin by filtering the mixture, and then wash the resin 2x using 0.2 mL of 50% (vol/vol) aqueous acetonitrile. Mix the filtrates for high-performance liquid chromatography (HPLC) purification. Use the following HPLC conditions. Column: YMC-Triat-C18 (4.6 mm internal diameter [i.d.], 150 mm, 5 mm); solvent gradient: solvent A-deionized water; solvent B-acetonitrile (0.1% TFA); flow time: 20 min, with acetonitrile from 10% to 90%; flow rate: 1 mL/min.
  11. Freeze the collected HPLC eluents overnight at -80 °C and lyophilize (-50 °C and <1 pa). For radiolabeling, dissolve the solid peptide in sodium acetate buffer (100 mM, pH 5.0) at a final concentration of 1 mg/mL as a stock buffer.

2. 68Ga radiolabeling

NOTE 68Ga was generated in-house at Nanjing First Hospital (Nanjing, China) using a 68Ge/68Ga generator.

  1. Pipette 5 µL of stock buffer into a 1.5 mL polypropylene container with a screw cap. Add 200 MBq [68Ga]GaCl3 (400 µL) to the container.
  2. Vortex the mixture for 5 s. Measure the pH using pH test strips. Adjust the pH to 4-4.5 with NaOH (0.1 M).
    NOTE: An appropriate pH is critical for complexation between 68Ga and DOTA.
  3. Incubate the solution at room temperature for 5-10 min. Subject the reaction mixture to radio-HPLC for radiolabeling yield analysis under the following conditions: column: YMC-Triat-C18 (4.6 mm i.d., 150 mm, 5 mm); solvent gradient: solvent A-deionized water; solvent B-acetonitrile (0.1% TFA); flow time: 20 min, with acetonitrile from 10% to 90%; flow rate: 1 mL/min.
    ​NOTE: Radio thin-layer chromatography (TLC) can be used as an alternative approach to examine radiolabeling yield. The suggested TLC elution buffer is 0.1 M Na3C6H5O7, pH 4.

3. Tracer stability test

  1. Tracer stability test in PBS
    1. Add [68Ga]DPA (10 µL, 3.7 MBq, in NaOAc) to the PBS (990 µL). Incubate at 37 °C for 1, 2, and 4 h with slight agitation.
    2. Collect 200 µL of the solution at each time point. Inject it into the radio-HPLC for analysis.
  2. Tracer stability in mouse serum
    1. Add [68Ga]DPA (10 µL, ~3.7 MBq, in NaOAc) to the mouse serum (90 µL, freshly prepared). Incubate at 37 °C for 1, 2, and 4 h with slight agitation.
    2. Collect 20 µL of the solution at each time point. Add MeCN and water (100 µL, 1:1, v/v).
    3. Centrifuge the mixture for 10 min (5,000 × g, 25 °C). Analyze the supernatant using radio-HPLC.

4. Analysis of PD-L1 expression by flow cytometry

  1. Prepare culture medium by supplementing RPMI-1640 medium with 10% (vol/vol) fetal bovine serum and 1% penicillin-streptomycin (vol/vol). Resuspend the U87MG cells in culture medium, and seed in 12-well plates at a density of 105 cells/well. Place the cells in an incubator (5% CO2, 37 °C), and culture for at least 24 h without disturbing.
  2. Wash the cells with 0.5 mL of PBS and add 250 μL of trypsin-EDTA (0.25%). Place the cells back in the incubator (5% CO2, 37 °C) for 2 min.
  3. Add 1 mL of culture medium to stop the cell dissociation. Add medium to the cells to detach them from the dishes by pipetting up and down and collect them in 1.5 mL tubes. Centrifuge the cells for 5 min (100 × g).
  4. Remove the supernatant and resuspend the cells in 1 mL of PBS. Centrifuge the cells for 5 min (100 × g). Repeat this step one more time.
  5. Dilute the fluorescein isothiocyanate (FITC)-conjugated PD-L1 antibody with 3% bovine serum albumin (BSA) to 20 nmol/L. Add to the cells and incubate at 4 °C for 1 h.
  6. Centrifuge the cells for 5 min (100 × g), followed by washing with cold PBS twice. Analyze the PD-L1-positive cells using a flow cytometer and analysis software.

5. Immunocytochemistry

  1. Seed the U87MG cells in glass bottom cell culture dishes (35 mm) at a density of 2.5 × 105 cells per well. When 60% confluency is reached, aspirate the culture medium and add 1 mL of PBS. Gently shake several times and aspirate. Perform the washing step 3x.
  2. Add 500 µL of 4% paraformaldehyde to the dishes. Place the cells at room temperature and fix for 30 min.
  3. Wash the cells 3x with PBS. Add 1 mL of 3% BSA (wt/vol, in PBS) and block the fixed cells for 2 h at room temperature.
  4. Remove the 3% BSA and directly incubate the cells with primary anti-PD-L1 antibody (mAb,1:100, diluted in 3% BSA) overnight at 4 °C.
    NOTE: After blocking the cells with BSA, do not wash with PBS.
  5. Wash the cells 3x with 3% BSA buffer. Incubate the cells with FITC-conjugated anti-human IgG Fc secondary antibody (1:500, diluted in PBS) for 1 h.
  6. Wash the cells 3x with PBS. Add 0.5 mL of DAPI (1 µg/mL) to the cells and incubate at room temperature for 1 h. Wash the stained cells 3x with PBS, and observe using confocal fluorescence microscope.

6. Cellular uptake and inhibition experiment

  1. Cellular uptake experiment
    1. Culture the U87MG cells in 12-well plates until 80% confluency is reached. Remove the medium and wash the cells with 0.5 mL of PBS.
    2. Dilute the [68Ga]DPA in fresh medium to a concentration of 74 KBq/mL. Add 0.5 mL of the diluted [68Ga]DPA buffer to each well.
    3. Incubate the cells with [68Ga]DPA at 37 °C for different durations (10, 30, 40, and 120 min). Aspirate the medium using a pipette. Wash the cells with PBS (0.5 mL) three times.
    4. Add NaOH solution (0.5 M, 300 µL per well) to lyse the cells. After 30 s, collect the viscous cell lysates in 1.5 mL tubes.
    5. Wash the plate with 0.4 mL of PBS twice. Collect the washing solution in the above 1.5 mL tube.
    6. Start the built-in computer of the automatic gamma counter; put the tubes into the built-in shelf. After loading all the samples onto the conveyor, press the START button. Results are calculated in the internal software. The read-out records the decay-correlated counts per minute (CPM) of each tube.
  2. Competitive binding assay
    1. Culture the U87MG cells in 12-well plates until 80% confluency is reached. Remove the medium and wash the cells with 0.5 mL of PBS.
    2. Dilute [68Ga]DPA in fresh medium to a concentration of 74 KBq/mL. Dissolve an appropriate amount of BMS202 compounds in 10% DMSO to yield a 10 mM concentration (400 µL).
    3. Dilute 4 µL of 10 mM BMS202 in 396 µL of PBS to obtain a concentration of 100 µM. Repeat this step to yield various concentrations of BMS202 (1 µM, 10 nM, 100 pM, and 1 pM).
    4. Add 0.5 mL of the diluted [68Ga]DPA buffer to each well (0.37 MBq per well). Add 5 µL of the BMS202 solutions to each well (three wells for each concentration). Incubate the cells in a cell incubator at 37 °C for 120 min.
    5. Aspirate the medium using a pipette. Wash the cells with 3 x 0.5 mL of PBS.
    6. Add the NaOH solution (0.5 M, 300 µL per well) to lyse the cells. After 30 s, collect the viscous cell lysates into 1.5 mL tubes. Wash the plate with 2 x 0.4 mL of PBS.
    7. Collect the washing solution in the above 1.5 mL tube. Put the tubes into the built-in shelf of the automatic gamma counter.
    8. Follow the same procedures as step 6.1.6.

7. PET imaging

NOTE: Perform small animal PET imaging, using a micro PET scanner that provides 159 transverse axial sections spaced 0.796 mm apart (center-to-center), with a horizontal field of view of 10 cm and an axial field of view of 12.7 cm. All data collected in the list mode are organized into three-dimensional sinograms. The Fourier is then reassembled into two-dimensional sinograms (frame × min: 4 × 1, 8 × 2, 8 × 5).

  1. Use male, 5-8-week-old BALB/C nude mice in this study. Collect the U87MG cells following steps 4.1-4.4 and aspirate the cells into a 0.5 mL syringe. Subcutaneously inject the cells into the mice (1 × 106 cells per tumor, two tumors per mouse). Monitor tumor growth after injection until the tumor volume is 100-300 mm3.
  2. Anesthetize the mice using 1%-2% (v/v) isoflurane (1 mL/min). Turn on the heating device and keep the animal bed of PET at 37 °C. 
  3. Put the anesthetized mice in the right position on the animal bed of the PET machine. Apply ophthalmic ointment to both eyes to prevent dryness.
    CAUTION: Keep the mice in the prone position to avoid death during scanning. During the whole imaging process, administer isoflurane flow (1.0 mL/min) via the nose using a preinstalled tube.
  4. Adjust the animal bed position via the control panel. Inject the tracers (10-17 MBq/100-200 µL) intravenously through a preinstalled tail vein catheter.
  5. Create a scanning workflow in a host computer using the referenced software (see Table of Materials) Create a study folder and set the acquisition protocol as per the manufacturer's protocol. Perform dynamic scans (60 min for each mouse) on all mice in 3D list mode.
  6. Define a histogram protocol and a reconstruction protocol following the manufacturer' protocol. Use Hanning's filter with a Nyquist cutoff of 0.5 cycle/pixel to reconstruct PET dynamic images (25-30 min and 55-60 min) through filtered back-projection. Generate maximum intensity projection (MIP) images for all mice.
  7. Combine the protocols in a workflow and run the workflow. Analyze the resulting three-dimensional images using the software, following the manufacturer's protocol.
    NOTE: Use the simulation software to select the volumes of interest. Radioactivity is decay-corrected to the injection time and presented as the percentage of the total injection dose/per gram tissue (% ID/g).

8. Ex vivo biodistribution

  1. Administer [68Ga]DPA (1.85 MBq/100 µL) to the U87MG-bearing BALB/C nude mice through tail vein injection. Anesthetize the mice using 1%-2% (v/v) isoflurane (1 mL/min), then sacrifice three mice via cervical dislocation after injection for 5, 30, 60, and 120 min.
    NOTE: The individuals demonstrating this procedure should be trained in the technical skills of cervical dislocation to ensure the loss of consciousness is rapidly induced. This will ensure that the euthanasia procedures in this experiment are all humanely performed.
  2. After death is confirmed, open the chest wall of the mice. Then, open the heart. Use a 1 mL syringe to draw blood; squeeze the blood from the syringe into a radioimmunoassay (RIA) tube (13 mm in diameter) for the gamma counter.
  3. Excise the major organs and tumors and place them in RIA tubes (13 mm in diameter) for the gamma counter. Major organs include the total blood, heart, thymus, liver, spleen, bone, stomach, kidneys, muscle, intestinal lymph node, small intestine, pancreas, testis, brain, and lungs. Weigh all the organs.
  4. Measure the radioactivity within the collected organs using an autogamma counter and decay-correct the values. Calculate the percentage of injected dose per gram of wet tissue (% ID/g).

9. Immunohistochemistry

  1. Collect the glioma tissues and wash them 3x with PBS. Put the fresh tissues in 4% paraformaldehyde and fix overnight at 4 °C.
  2. Embed the fixed tissues in paraffin and section them to a thickness of 10 µm. Place the sections in an incubator (60 °C) and incubate for 2 h. Dewax and hydrate the sections by incubating for 10 min each in the following: xylene (twice), absolute alcohol, 95% alcohol, 90% alcohol, 80% alcohol, 75% alcohol.
  3. Put the sections in 0.01 M sodium citrate and heat them to 92-95 °C. Maintain the temperature for 40 min to achieve antigen retrieval.
  4. Add 200 µL of H2O2 solution (3%) to the sections and inactivate the endoperoxidases for 10 min at room temperature. Block the non-specific sites by treatment with 3% BSA for 2 h at room temperature.
  5. Incubate the sections in primary anti-PD-L1 antibody (mAb, 1:100, diluted in 3% BSA) overnight at 4 °C.
    NOTE: After blocking with BSA, do not wash with PBS.
  6. Wash the sections 3x with PBS. Incubate the sections with HRP-labeled goat anti-rabbit secondary antibody (1:500, diluted in PBS) at room temperature for 1 h.
  7. Wash the cells 3x with PBS. Add 200 µL of 3,3-diaminobenzidine (DAB) working solution (solution A: solution B: solution C = 1:1:18) to the sections and incubate for 5 min in the dark.
  8. Wash the sections 3x with PBS. Add 500 µL of hematoxylin solution (100%), and incubate for 5 min at room temperature. Wash the sections with water for 30 s. Put the sections into differentiation solution (75% alcohol:HCL = 99:1) for 30 s. Wash the sections using water for 1 min.
  9. Dehydrate the samples by sequentially incubating with 75% alcohol, 80% alcohol, 90% alcohol, 95% alcohol, absolute alcohol, and xylene (twice) (10 min each). Mount all the sections using neutral resin and observe them under an optical microscope.

Subscription Required. Please recommend JoVE to your librarian.

Representative Results

[68Ga]DPA radiolabeling and stability
The model peptide, DPA, is an effective PD-L1 antagonist. DOTA-DPA was obtained with >95% purity and a yield of 68%. The mass of DOTA-DPA is experimentally observed at 1,073.3 ([M+2H]2+). 68Gallium is considered a suitable radionuclide to label peptides for PET imaging, and therefore was chosen for this study. To radiolabel DPA with 68Ga (half-life: 68 min), DOTA-PEG3-DPA was synthesized (Figure 1A). DOTA was used as a chelator for the 68Ga radiolabeling. To space DOTA and DPA, PEG3 was used as a linker. The [68Ga]-DOTA-PEG3-DPA (referred to as [68Ga]DPA in the following text) showed high radiochemical yield (>95%) and radiochemical purity (>95%) (Table 1). A tracer stability test was also performed using HPLC, and the results showed that [68Ga]DPA had great stability both in PBS and mouse serum. The 68Ga decomposition or peptide hydrolysis was not detected after a 4 h incubation at 37 °C (Figure 1B).

Expression of PD-L1 in U87MG cells
A previous study showed that an increased expression of PD-L1 correlated with poor patient survival in glioblastoma tumors, indicating that PD-L1 may be a remarkable prognostic biomarker and therapeutic target in glioblastoma48. Therefore, a human glioblastoma cell line, U87MG, was used to establish a tumor model to determine the efficacy of [68Ga]DPA in PET/CT for PD-L1 tumor imaging. The flow cytometry results suggested that approximately 60% of the U87MG cells were PD-L1 positive (Figure 2A). Moreover, immunofluorescent staining confirmed the strong expression of PD-L1 in the U87MG cells (Figure 2B). Together, these data demonstrated that the U87MG cell line was suitable for this study.

Cellular uptake and specificity of [68Ga]DPA
The uptake of [68Ga]DPA by U87MG cells presented a time-dependent pattern. When a PD-L1 inhibitor, BMS202, was used as a blocking agent, the binding portion and the uptake of [68Ga]DPA were significantly reduced (Figure 3A). A competitive binding assay further examined the binding affinity (Ki) of BMS202 to the U87MG cells. The estimated binding affinity was 43.8 ± 8.6 nmol/L for BMS202 when [68Ga]DPA was used as a competitor (Figure 3B).

[68Ga]DPA PET imaging of tumor models
PET imaging of [68Ga]DPA was performed in U87MG tumor-bearing BALB/C nude mice. [68Ga]DPA was administered through intravenous injection until the U87MG tumor grew to 100 mm3. Whole-body PET images revealed high [68Ga]DPA accumulation in the tumor after 30 and 60 min of injection, and showed the highest accumulation in the kidney and bladder (Figure 4A). To confirm whether [68Ga]DPA specifically accumulated in PD-L1-positive tumors, another mouse model bearing the PanNET cell line Bon-1 was used as a negative control. A parallel experiment demonstrated little [68Ga]DPA accumulation in Bon-1 tumors at 60 min post-injection (Figure 4B).

To clarify this difference, immunohistochemical staining was conducted to analyze PD-L1 expression in tumor tissues. The results revealed that the U87MG cells presented considerable PD-L1 expression (Figure 5A,C), but not the Bon-1 tumor (Figure 5B,C). These data were consistent with the PET results. Therefore, it is possible that the different tumor cell growth statuses resulted in different PD-L1 expression (e.g., tissue necrosis). To verify this, hematoxylin and eosin (H&E) staining was performed. As expected, a similar cell morphology was observed between the two tumor tissues (Figure 5D).

Ex vivo biodistribution of [68Ga]DPA in U87MG tumors
The ex vivo biodistribution study was also conducted using U87MG-bearing mice (Table 2). The results showed a rapid clearance in blood and most analyzed organs, including the heart, liver, lung, and muscle. The kidney accumulated the highest amount of radioactivity and showed a clearance rate of 0.12% ID/(g∙min) from 5 min to 120 min. The tumor exhibited uptake of the second-highest tracer uptake at all time points. In addition, from 5 min to 60 min post-injection, the tumor presented a lower tracer clearance rate of 0.027% ID/(g∙min). For blood, the clearance rate was 0.069% ID/(g∙min), while for muscle, the clearance rate was 0.037% ID/(g∙min).

Figure 1
Figure 1: [68Ga]DPA radiolabeling and stability. (A) The chemical structure of [68Ga]DPA and the schematic representation of its binding to PD-L1 expressing tumor cells. (B) HPLC curves showing the radioactivity of [68Ga]DPA after incubation with PBS or mouse serum for 0.5, 2, and 4 h. This figure was modified from Hu et al.47. Abbreviations: DPA = dodecapeptide antagonist; PD-L1 = programmed death-ligand 1; PBS = phosphate-buffered saline; HPLC = high-performance liquid chromatography. Please click here to view a larger version of this figure.

Figure 2
Figure 2: Expression of PD-L1 in the U87MG cell line. (A) The expression of PD-L1 in the U87MG cell line was measured through flow cytometry analysis. (B) The expression of PD-L1 in U87MG cells was measured by immunofluorescence staining assay. Scale bar = 100 µm. This figure was modified from Hu et al.47. Abbreviations: PD-L1 = programmed death-ligand 1; SSC = side scatter; FITC = fluorescein isothiocyanate. Please click here to view a larger version of this figure.

Figure 3
Figure 3: Cellular uptake and inhibition of [68Ga]DPA. (A) The uptake of U87MG cells when incubated with [68Ga]DPA (0.74 MBq/mL) or [68Ga]DPA (0.74 MBq /mL) + BMS202 (100 µmol/L) for different durations. (B) Competitive binding of [68Ga]DPA (0.74 MBq /mL) to the U87MG cells following incubation with BMS202. The Ki value is shown in the panel. This figure was modified from Hu et al.47. Abbreviations: DPA = dodecapeptide antagonist; %AD = administered dose (with respect to the binding portion). Please click here to view a larger version of this figure.

Figure 4
Figure 4: PET imaging of [68Ga]DPA in PD-L1-overexpressing U87MG tumors. (A,B) PET-CT images showing the distribution of [68Ga]DPA in U87MG-bearing mice (A) and Bon-1-bearing mice (negative control, B) after intravenous injection (~18.5 MBq) for 30 min and 60 min. Representative maxiumum-intensity projection (MIP) (top panel) and transverse PET-CT images (bottom panel) are presented. The tumor positions are marked by white dashed circles. This figure was modified from Hu et al.47. Abbreviations: DPA = dodecapeptide antagonist; PD-L1 = programmed death-ligand 1; PET-CT = positron emission tomography-computed tomography; MIP = maxiumum-intensity projection; p.i. = post-injection. Please click here to view a larger version of this figure.

Figure 5
Figure 5: Immunohistochemical analysis of [68Ga]DPA-treated tumors. (A,B) Whole-section immunohistochemical images of PD-L1 in (A) U87MG and (B) Bon-1 tumors. (C) Enlarged pictures of the marked areas in A and B. (D) H&E staining of U87MG and Bon-1 tumor. Scale bars = 100 µm (C,D). This figure was modified from Hu et al.47. Abbreviations: DPA = dodecapeptide antagonist; PD-L1 = programmed death-ligand 1; H&E = hematoxylin and eosin. Please click here to view a larger version of this figure.

Tracers [68Ga]DPA
Radiochemical yield (%) >95
Molar activity (GBq µmol-1) 37 ± 8
Radiochemical puritya (%) >95

Table 1: Radiolabeling and quality control of [68Ga]DPA. Radiochemical yield, molar activity, and radiochemical purity of [68Ga]DPA. Data are represented as the mean ± SD (n = 7). This table was modified from Hu et al.47. Abbreviation: DPA = dodecapeptide antagonist. aRadiochemical purity of [68Ga]DPA was analyzed by reverse-phase HPLC under an optimized condition: 1) column: YMC-Triat-C18 (4.6 mm i.d., 150 mm, 5 mm); 2) solvent gradient: solvent A-deionized water; solvent B-acetonitrile (0.1% trifluoroacetic acid); flow time: 20 min, with acetonitrile from 10% to 90%; flow rate of 1 mL/min.

5 min 30 min 60 min 120 min
blood 3.89 ±0.43 1.55 ±1.07 0.11 ±0.02 0.05 ±0.01
heart 1.19 ±0.39 0.52 ±0.33 0.06 ±0.02 0.05 ±0.02
liver 1.06 ±0.26 0.59 ±0.43 0.19 ±0.02 0.16 ±0.04
spleen 0.98 ±0.14 0.68 ±0.67 0.14 ±0.06 0.09 ±0.03
lung 1.64 ±0.42 1.03 ±0.9 0.13 ±0.05 0.09 ±0.02
kidney 19.23 ±1.95 16.13 ±1.51 11.5 ±0.44 5.2 ±0.31
stomach 1.54 ±0.1 0.61 ±0.35 0.08 ±0.01 0.08 ±0.03
intestinal 0.72 ±0.27 0.47 ±0.35 0.08 ±0.02 0.06 ±0.03
pancreas 1.88 ±0.28 0.77 ±0.75 0.16 ±0.03 0.13 ±0.03
muscle 2.21 ±0.27 0.71 ±0.37 0.18 ±0.02 0.14 ±0.04
bone 2.18 ±0.11 0.85 ±0.51 0.26 ±0.09 0.14 ±0.06
brain 0.19 ±0.04 0.11 ±0.08 0.03 ±0.01 0.02 ±0.01
tumor 4.5 ±0.32 3.77 ±0.27 2.99 ±0.03 0.89 ±0.19
fat 2.09 ±0.49 0.81 ±0.12 0.27 ±0.07 0.1 ±0.07

Table 2: Biodistribution of [68Ga]DPA in U87MG tumor-bearing mice after administration for different durations (n = 3 per time point). This table is modified from Hu et al.47. Abbreviation: DPA = dodecapeptide antagonist.

Subscription Required. Please recommend JoVE to your librarian.


The critical steps described in this method include the efficient labeling of 68Ga to DPA and choosing a suitable time window for PET imaging, which must perfectly match the pharmacodynamic pattern of DPA in the tumor.

In contrast to IHC, PET imaging enables real-time detection of whole-body PD-L1 expression in a noninvasive manner, allowing the visualization of each positive area in a heterogeneous tumor6,7. Peptides were chosen as ligands to avoid the disadvantages of antibodies and small molecules. Antibodies with large molecular weights generally have long circulating half-lives, which causes higher toxicity to healthy organs. The clearance of small molecules is usually too rapid to attain the required tumor retention. The molecular weight of peptides ranges between that of antibodies and small molecules. This enables peptide-based radiotracers to achieve both long-term tumor retention and good tissue penetration with minimal toxicity13,49,50,51,52,53. Importantly, the utility of the D-peptide DPA, rather than the commonly reported L-peptides, confer the [68Ga]DPA with a remarkably prolonged metabolic half-life. Moreover, DPA is positively charged and hydrophilic in vivo, and hence has high solubility and can avoid nonspecific targeting in blood, facilitating the generation of PET images with high imaging quality.

Notably, successful 68Ga radiolabeling requires a specific pH and no interference from transition metal ions, such as Cu (II) and Fe (III) cations. In some cases, the Cu2+ contamination leads to low radiochemical yield. Therefore, it is critical to ensure that all the containers and pipette tips are not contaminated. In addition, in this method, U87MG was used for tumor inoculation. Although PD-L1 expression in U87MG xenografts was verified in previous studies, its expression varies across individual animals. Therefore, the absolute uptake of the tracer in the U87MG tumors varied across individual mice. To ensure effective tracer uptake in the tumors, animals with an appropriate tumor size (500 mm3 < volume < 100 mm3) must be selected for PET scanning.

One of the limitations of [68Ga]DPA is that the binding affinity of DPA to PD-L1 is relatively low compared to several other PD-L1 targeting peptides, such as WL12, which makes it unsuitable for tumors with relatively low PD-L1 expression26,47. Further modification of the D-peptide will improve its specific binding capacity. In addition, to enhance the imaging effect of [68Ga]DPA, the formulation of the injection strategy can be optimized, for example, by concurrently injecting unlabeled DPA before [68Ga]DPA to block the nonspecific binding sites54,55,56.

In conclusion, this study developed a noninvasive and real-time method to track PD-L1 distribution in the whole body of living animals using [68Ga]DPA as a radiotracer. The results revealed a relatively high, in vivo specifical binding affinity, favorable stability, and excellent imaging capacity of [68Ga]DPA, suggesting that [68Ga]DPA-PET is a promising approach for visualizing PD-L1-overexpressing tumors. Furthermore, this technique can also be applied to the treatment of PD-L1 positive tumors when labeling DPA with other radionuclides, such as 177Lu and 225Ac. Therefore, the DPA radiolabeling technique not only overcomes the limitation of IHC dependent diagnosis, but also provides a new option for treatment.

Subscription Required. Please recommend JoVE to your librarian.


No competing interests are declared.


This study was supported by the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences (no. 2022-RC350-04) and the CAMS Innovation Fund for Medical Sciences (nos. 2021-I2M-1-026, 2022-I2M-1-026-1, 02120101, 02130101, and 2022-I2M-2-002).


Name Company Catalog Number Comments
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) Merck 60239-18-1 68Ga  chelation
3,3-diaminobenzidine (DAB) Kit Sigma-Aldrich D7304-1SET Immunohistochemistry
anti-PD-L1 monoclonal antibody Wuhan Proteintech 17952-1-ap Immunohistochemistry: primary antibody
BMS202 Selleck 1675203-84-5 Competitive binding assay: inhibitor
BSA Merck V900933 Immunofluorescent : blocking 
DAPI Merck D9542 Immunofluorescent: staining of nucleus
Dichloromethane (DCM) Merck 34856 Solvent
DIPEA Merck 3439 Peptide coupling
EDC·HCl Merck E6383 Activation of DOTA
FBS Gibco 10099 Cell culture: supplement
FITC-conjugated anti-human IgG Fc Antibody Biolegend 409310 Immunofluorescent: secondary antibody
FITC-conjugated anti PD-L1 antibody Biolegend 393606 Flow cytometry: direct antibody
HCTU Energy Chemical E070004-25g Peptide coupling
HRP labeled goat anti-rabbit antibody Servicebio GB23303 Immunohistochemistry: secondary antibody
Hydroxysuccinimide (NHS) Merck 130672 Activation of DOTA
MeCN Merck PHR1551 Solvent
Morpholine Merck 8.06127 Fmoc- deprotection
NMP Merck 8.06072 Solevent
Paraformaldehyde Merck 30525-89-4 Fixation of tissues
PBS Gibco 10010023 Cell culture: buffer
Penicillin-streptomycin  Gibco 10378016 Cell culture: supplement
RIA tube PolyLab P10301A As tissue sample container
RPMI-1640 medium Gibco 11875093 Cell culture: basic medium
Sodium acetate Merck 1.06264 Salt for buffer
Trypsin-EDTA Gibco 25200056 Cell culture: dissociation agent
U87MG cell line Procell Life Science & Technology Co CL-0238 Cell model
68Ge/68Ga generator Isotope Technologies Munich, ITM Not applicable Generation of [68Ga]
Autogamma counter Perkin Elmer  Wizard2 Detection of radioactivity
Confocal fluorescent microscopy Keyence Observation of immunofluorescent results
Flow cytometer Becton Dickinson, BD LSRII Monitoring the PD-L1 positive cells
High-performance liquid chromatography (HPLC) SHIMAZU LC-20AT  Purification of DPA peptide
PET scanner Siemens Medical Solutions Inveon MultiModality System PET imaging
Optical microscopy Nikon  Eclipse E100 Observation of immunohistochemistry results
Solid phase peptide synthesizer Promega Vac-Man Laboratory Vacuum Manifold LOT#11101 Synthesis of DPA-DOTA peptide
ASIPro Siemens Medical Solutions Not applicable Analysis of PET-CT results
FlowJo Becton Dickinson, BD FlowJo 7.6.1 Analysis of the flow cytometer results
Inveon Acquisition Workplace (IAW) Siemens Medical Solutions Not applicable Management of PET mechine
Prism Graphpad Prism 8.0 Analysis of the data 



  1. Doroshow, D. B., et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Natire Reviews Clinical Oncology. 18 (6), 345-362 (2021).
  2. Krutzek, F., Kopka, K., Stadlbauer, S. Development of radiotracers for imaging of the PD-1/PD-L1 axis. Pharmaceuticals. 15 (6), 747 (2022).
  3. Topalian, S. L., Drake, C. G., Pardoll, D. M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 27 (4), 450-461 (2015).
  4. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nature Reviews Cancer. 12 (4), 252-264 (2012).
  5. Xiao, Z., et al. PEIGel: A biocompatible and injectable scaffold with innate immune adjuvanticity for synergized local immunotherapy. Materials Today Bio. 15, 100297 (2022).
  6. Teng, M. W. L., Ngiow, S. F., Ribas, A., Smyth, M. J. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Research. 75 (11), 2139-2145 (2015).
  7. Dolled-Filhart, M., et al. Development of a companion diagnostic for pembrolizumab in non-small cell lung cancer using immunohistochemistry for programmed death ligand-1. Archives of Pathology & Laboratory Medicine. 140 (11), 1243-1249 (2016).
  8. Meng, X. J., Huang, Z. Q., Teng, F. F., Xing, L. G., Yu, J. M. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy. Cancer Treatment Reviews. 41 (10), 868-876 (2015).
  9. Hakozaki, T., Hosomi, Y., Kitadai, R., Kitagawa, S., Okuma, Y. Efficacy of immune checkpoint inhibitor monotherapy for patients with massive non-small-cell lung cancer. Journal of Cancer Research and Clinical Oncology. 146 (11), 2957-2966 (2020).
  10. Haslam, A., Prasad, V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. Jama Network Open. 2 (5), 192535 (2019).
  11. Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., Gambhir, S. S. Molecular imaging in drug development. Nature Reviews Drug Discovery. 7 (7), 591-607 (2008).
  12. Zhang, L., et al. Recent developments on PET radiotracers for TSPO and their applications in neuroimaging. Acta Pharmaceutica Sinica B. 11 (2), 373-393 (2021).
  13. Sun, J., et al. Imaging-guided targeted radionuclide tumor therapy: From concept to clinical translation. Advanced Drug Delivery Reviews. 190, 114538 (2022).
  14. Xu, M., et al. Preclinical study of a fully human Anti-PD-L1 antibody as a theranostic agent for cancer immunotherapy. Molecular Pharmaceutics. 15 (10), 4426-4433 (2018).
  15. Niemeijer, A. N., et al. Whole body PD-1 and PD-L1 positron emission tomography in patients with non-small-cell lung cancer. Nature Communications. 9 (1), 4664 (2018).
  16. Mayer, A. T., et al. Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging. Journal of Nuclear Medicine. 58 (4), 538-546 (2017).
  17. Lv, G., et al. PET Imaging of tumor PD-L1 expression with a highly specific nonblocking single-domain antibody. Journal of Nuclear Medicine. 61 (1), 117-122 (2020).
  18. Li, D., et al. Immuno-PET imaging of 89Zr labeled anti-PD-L1 domain antibody. Molecular Pharmaceutics. 15 (4), 1674-1681 (2018).
  19. Lesniak, W. G., et al. PD-L1 detection in tumors using [(64)Cu]Atezolizumab with PET. Bioconjugate Chemistry. 27 (64), 2103-2110 (2016).
  20. Kristensen, L. K., et al. CD4(+) and CD8a(+) PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models. Theranostics. 9 (26), 8221-8238 (2019).
  21. Christensen, C., Kristensen, L. K., Alfsen, M. Z., Nielsen, C. H., Kjaer, A. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody. European Journal of Nuclear Medicine and Molecular Imaging. 47 (5), 1302-1313 (2020).
  22. Bensch, F., et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer. Nature Medicine. 24 (12), 1852-1858 (2018).
  23. Gonzalez Trotter, D. E., et al. In vivo imaging of the programmed death ligand 1 by 18F PET. Journal of Nuclear Medicine. 58 (11), 1852-1857 (2017).
  24. Lv, G., et al. Promising potential of a 18F-labelled small-molecular radiotracer to evaluate PD-L1 expression in tumors by PET imaging. Bioorganic Chemistry. 115, 105294 (2021).
  25. Miao, Y., et al. One-step radiosynthesis and initial evaluation of a small molecule PET tracer for PD-L1 imaging. Bioorganic & Medicinal Chemical Letters. 30 (24), 127572 (2020).
  26. Kumar, D., et al. Peptide-based PET quantifies target engagement of PD-L1 therapeutics. The Journal of Clinical Investigation. 129 (2), 616-630 (2019).
  27. Powles, T., et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 515 (7528), 558-562 (2014).
  28. Herbst, R. S., et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 515 (7528), 563-567 (2014).
  29. Marciscano, A. E., Gulley, J. L. Avelumab demonstrates promise in advanced NSCLC. Oncotarget. 8 (61), 102767-102768 (2017).
  30. Vaddepally, R. K., Kharel, P., Pandey, R., Garje, R., Chandra, A. B. Review of indications of FDA-approved immune checkpoint inhibitors per NCCN guidelines with the level of evidence. Cancers. 12 (3), 738 (2020).
  31. Antonia, S. J., et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. The New England Journal of Medicine. 377 (20), 1919-1929 (2017).
  32. Wang, D. Y., et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncology. 4 (12), 1721-1728 (2018).
  33. Sgouros, G., Bodei, L., McDevitt, M. R., Nedrow, J. R. Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nature Reviews Drug Discovery. 19 (9), 589-608 (2020).
  34. (US) M. M. M, et al. Macrocyclic inhibitors of the pd-1/pd-l1 and cd80(b7-1)/pd-l1 protein/protein interactions. United States patent. , US-2017260237-A1 (2014).
  35. Chatterjee, S., et al. Rapid PD-L1 detection in tumors with PET using a highly specific peptide. Biochemical and Biophysical Research Communications. 483 (1), 258-263 (2017).
  36. De Silva, R. A., et al. Peptide-based 68Ga-PET radiotracer for imaging PD-L1 expression in cancer. Molecular Pharmaceutics. 15 (9), 3946-3952 (2018).
  37. Lesniak, W. G., et al. Development of [18F]FPy-WL12 as a PD-L1 specific PET imaging peptide. Molecular Imaging. 18, 1536012119852189 (2019).
  38. Zhou, X., et al. First-in-humans evaluation of a PD-L1-binding peptide PET radiotracer in non-small cell lung cancer patients. Journal of Nuclear Medicine. 63 (4), 536-542 (2022).
  39. Hu, K., et al. Developing native peptide-based radiotracers for PD-L1 PET imaging and improving imaging contrast by pegylation. Chemical Communications. 55 (29), 4162-4165 (2019).
  40. Liu, H., et al. A novel small cyclic peptide-based 68Ga-Radiotracer for positron emission tomography imaging of PD-L1 expression in tumors. Molecular Pharmaceutics. 19 (1), 138-147 (2022).
  41. Rabideau, A. E., Pentelute, B. L. A D-amino acid at the N-terminus of a protein abrogates its degradation by the N-end rule pathway. ACS Central Science. 1 (8), 423-430 (2015).
  42. Uppalapati, M., et al. A potent D-protein antagonist of VEGF-A is nonimmunogenic, metabolically stable, and longer-circulating in vivo. ACS Chemical Biology. 11 (4), 1058-1065 (2016).
  43. Garton, M., et al. Method to generate highly stable D-amino acid analogs of bioactive helical peptides using a mirror image of the entire PDB. Proceedings of the National Academy of Sciences. 115 (7), 1505-1510 (2018).
  44. Jia, F. J., et al. D-amino acid substitution enhances the stability of antimicrobial peptide polybia-CP. Acta Biochimica et Biophysica Sinica. 49 (10), 916-925 (2017).
  45. Carmona, G., Rodriguez, A., Juarez, D., Corzo, G., Villegas, E. Improved protease stability of the antimicrobial peptide Pin2 substituted with D-amino acids. Protein Journal. 32 (6), 456-466 (2013).
  46. Feng, Z., Xu, B. Inspiration from the mirror: D-amino acid containing peptides in biomedical approaches. Biomolecular Concepts. 7 (3), 179-187 (2016).
  47. Hu, K., et al. Whole-body PET tracking of a d-dodecapeptide and its radiotheranostic potential for PD-L1 overexpressing tumors. Acta Pharmaceutica Sinica. B. 12 (3), 1363-1376 (2022).
  48. Qiu, X. Y., et al. PD-L1 confers glioblastoma multiforme malignancy via Ras binding and Ras/Erk/EMT activation. Biochimica Et Biophysica Acta. Molecular Basis of Disease. 1864, 1754-1769 (2018).
  49. Hu, K., et al. Development of a stable peptide-based PET tracer for detecting CD133-expressing cancer cells. ACS Omega. 7 (1), 334-341 (2021).
  50. Jin, Z. -H., et al. Radiotheranostic agent 64Cu-cyclam-RAFT-c(-RGDfK-)4 for management of peritoneal metastasis in ovarian cancer. Clinical Cancer Research. 26 (23), 6230-6241 (2020).
  51. Hu, K., et al. Harnessing the PD-L1 interface peptide for positron emission tomography imaging of the PD-1 immune checkpoint. RSC Chemical Biology. 1 (4), 214-224 (2020).
  52. Hu, K., et al. PET imaging of VEGFR with a novel 64Cu-labeled peptide. ACS Omega. 5 (15), 8508-8514 (2020).
  53. Hu, K., et al. An in-tether chiral center modulates the helicity, cell permeability, and target binding affinity of a peptide. Angewandte Chemie International Edition. 55 (28), 8013-8017 (2016).
  54. Zhao, J., et al. Concurrent injection of unlabeled antibodies allows positron emission tomography imaging of programmed cell death ligand 1 expression in an orthotopic pancreatic tumor model. ACS Omega. 5 (15), 8474-8482 (2020).
  55. Moroz, A., et al. A preclinical assessment of 89Zr-atezolizumab identifies a requirement for carrier added formulations not observed with 89Zr-C4. Bioconjugate Chemistry. 29 (10), 3476-3482 (2018).
  56. Nedrow, J. R., et al. Imaging of programmed cell death ligand 1: impact of protein concentration on distribution of anti-PD-L1 SPECT agents in an immunocompetent murine model of melanoma. Journal of Nuclear Medicine. 58 (10), 1560-1566 (2017).


Cancer Research Programmed Death-Ligand 1 Expression Immune Checkpoint Blockade Therapy PD-1 PD-L1 Inhibitors Tumor Cells Immunohistochemistry (IHC) Positron Emission Tomography (PET) Radiolabeled Tracers Dextrorotary (D)-peptides Proteolytic Resistance Metabolic Half-lives 68Ga-labeled PD-L1-targeted D-peptide D-dodecapeptide Antagonist (DPA) Tumor-bearing Mice Stability Imaging Ability
Development of a <sup>68</sup>Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression
Play Video

Cite this Article

Zhang, L., Zhang, S., Wu, W., Wang,More

Zhang, L., Zhang, S., Wu, W., Wang, X., Shen, J., Wang, D., Hu, K., Zhang, M. R., Wang, F., Wang, R. Development of a 68Gallium-Labeled D-Peptide PET Tracer for Imaging Programmed Death-Ligand 1 Expression. J. Vis. Exp. (192), e65047, doi:10.3791/65047 (2023).

Copy Citation Download Citation Reprints and Permissions
View Video

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter